The Crisis Behind the Headlines
By Liza Shevchuk
BY PARIPOORNA SHARMA, VISION SCIENCE PHD STUDENT
Have you seen the headlines? The ones about more cuts to research funding? I have, as have my classmates, my mentors, and the patients whose hopes rest on the work we do. I am a second-year vision science PhD student, studying gene therapy in the retina. I came to Berkeley knowing that this path would be difficult. I was prepared to spend long hours in a lab, fix countless failed experiments, and work to help people win their battles against visually debilitating diseases. What I didn’t expect was having to fight to keep that work alive in an environment where science is treated as expendable.
The funding cuts to scientific research in the United States don’t affect just the news. They affect lives, especially for those of us still in training.
Since January 2025, the scientific landscape has been shifting dramatically, and its consequences will shadow my peers and I for the rest of our careers. When funding is slashed, the headlines talk about it in abstract terms and project what the long-term consequences might look like. But for us, these headlines are our reality. These cuts determine whether our mentors can continue to teach us, whether universities can support our work, and whether we can even finish our degrees. As research becomes increasingly more politicized, public trust in science erodes. We see grants vanish for new work, labs shrink in size, and talented postdocs walk away from research after years of investment in their fields. These are scientists who could train us and push scientific discovery forward. Without the support of postdocs, their expertise is lost and with it, the future of science is at risk.
This isn’t just about education either. When the government pulls funding from biomedical research, it slows progress to study and treat crippling conditions like Alzheimer’s, cancer, and opioid addiction.
In vision science, the stakes are just as high. Each year, millions of people face blindness from diseases like macular degeneration, diabetic retinopathy, and glaucoma. The therapies we’re developing now could one day give patients their sight back. These breakthroughs don’t happen overnight or by chance. They need resources, collaboration, equipment, and years of steady financial support. Cuts in funding don’t just delay innovation. They make some cures impossible to attain in our lifetime. In the end, it’s not just researchers who pay the price. Patients, families, and everyday people who depend on our science to change their lives are affected too.
So yes, I saw the headlines. I know what it really means, not just for me or my classmates, but for every person waiting for a treatment, a cure, or hope to see one day. It means that an entire generation of scientists may never get the chance to pursue discoveries they studied and trained for. It means that the decisions made in Washington D.C. right now could be the difference between a future filled with sight or a lifetime with darkness for millions of people.
Despite it all, we are still here. We are still in classrooms and labs, still asking questions and chasing answers. Our professors still show up to teach, even if their own positions may be uncertain. Our universities still fight to support us, even with dwindling resources. Despite the uphill battle, we still haven’t given up because we believe in what we are doing. We hope that eventually, the scientific community will be able to recover. I trust that when that time comes, the headlines tell a different story. A story of persistence, hope, and scientific discovery that brings people clarity and light.
About the Author
Paripoorna Sharma is a second-year Vision Science PhD student in the Flannery Lab. She earned a Bachelor of Science from UC San Diego in Human Biology. Her research focuses on new approaches to gene therapy to treat progressive retinal degenerative diseases. She aims to bridge the gap between basic vision research and patient-focused clinical applications.